Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14772MR)

This product GTTS-WQ14772MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14772MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8754MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ7058MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ12856MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ11598MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ7629MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ14468MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ9588MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ6763MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.